Vobramitamab duocarmazine
- Generic Name
- Vobramitamab duocarmazine
MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer
- First Posted Date
- 2024-01-29
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 17
- Registration Number
- NCT06227546
- Locations
- 🇺🇸
Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, United States
🇺🇸Hackensack Meridian Health, John Theurer Cancer Center, Hackensack, New Jersey, United States
🇺🇸Medstar Washington Hospital Center, Washington, District of Columbia, United States
A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors
- Conditions
- Non-small Cell Lung CancerAndrogen-Independent Prostatic CancerLaryngeal Squamous Cell CarcinomaMelanomaCastration-Resistant Prostatic CancerAndrogen-Insensitive Prostatic CancerHormone Refractory Prostatic CancerAnal CancerAnal NeoplasmHead and Neck Squamous Cell Carcinoma
- Interventions
- Biological: vobramitamab duocarmazine 2.0 mg (Arm A)Biological: vobramitamab duocarmazine 2.7 mg (Arm B)
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- MacroGenics
- Target Recruit Count
- 382
- Registration Number
- NCT05551117
- Locations
- 🇪🇸
Institut Catala d'Oncologia Hospitalet, Barcelona, Spain
🇵🇱Przychodnia Lekarska "KOMED", Konin, Wlkp, Poland
🇫🇷Gustave Roussy, Villejuif, Val De Marne, France
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
- Conditions
- Malignant MelanomaPancreatic Ductal CarcinomaRenal Cell CarcinomaAdvanced Solid TumorEpithelial Ovarian CancerCastration-Resistant Prostatic CancerHepatocellular Cancer
- Interventions
- First Posted Date
- 2022-03-24
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- MacroGenics
- Target Recruit Count
- 278
- Registration Number
- NCT05293496
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸Florida Cancer Specialists and Research Institute, Sarasota, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.